Atlas Trials

Anlotinib Combined With Chemotherapy for the Treatment of HER2 Negative Advanced Breast Cancer

Clinical trial NCT05334147 · UNKNOWN

Trial details

NCT number
NCT05334147
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
UNKNOWN
Study type
OBSERVATIONAL
HER2-negative Breast Cancer
Start date
2022-04-15
Primary completion
2025-02-01
Enrollment
315

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.